[
  {
    "id": "AC-1987",
    "track": "Orthopedics",
    "status": "Historical publication",
    "era": "1987",
    "title": "Dacron coracoclavicular reconstruction",
    "summary": "The Goldberg and Waddell case series reviewed nine grade III AC dislocations after woven Dacron reconstruction. The report included a transient brachial plexus lesion associated with heterotopic calcification.",
    "scope": "A historical, uncontrolled series. Preserve the adverse event and the reported follow-up when comparing modern procedures.",
    "sources": [
      {
        "label": "Original abstract",
        "url": "https://pubmed.ncbi.nlm.nih.gov/2955777/"
      }
    ],
    "topics": [
      "Medicine",
      "Sports medicine",
      "Biomaterials"
    ],
    "study": {
      "design": "Uncontrolled case series of nine grade III acromioclavicular dislocations treated with woven Dacron reconstruction.",
      "endpoint": "Clinical and radiographic assessment and functional evaluation with an isokinetic dynamometer.",
      "review": "Check available follow-up and ascertainment of complications, including the transient brachial plexus lesion. Keep the numerator and case-series denominator visible."
    }
  },
  {
    "id": "AC-COMP",
    "track": "Orthopedics",
    "status": "Literature comparison",
    "era": "2019 publication",
    "title": "Operative and nonoperative AC joint management",
    "summary": "The original review map included surgical versus conservative treatment for adult acromioclavicular dislocation as a same-joint comparator.",
    "scope": "Use the systematic review to frame comparisons. Extract eligibility, bias, and outcome definitions before making effect estimates.",
    "sources": [
      {
        "label": "Cochrane review",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31604007/"
      }
    ],
    "topics": [
      "Medicine"
    ]
  },
  {
    "id": "ACL-BEAR",
    "track": "Orthopedics",
    "status": "Literature comparison",
    "era": "2020 publication",
    "title": "Bridge-enhanced ACL repair",
    "summary": "The earlier orthopedic review included scaffold-assisted ACL bridging as a human comparator for repair versus reconstruction.",
    "scope": "Compare trial design, tissue, indication, and endpoints before applying any lesson to a different attachment site.",
    "sources": [
      {
        "label": "Randomized ACL trial",
        "url": "https://pubmed.ncbi.nlm.nih.gov/32298131/"
      }
    ],
    "topics": [
      "Medicine"
    ]
  },
  {
    "id": "CUFF-2024",
    "track": "Orthopedics",
    "status": "Literature comparison",
    "era": "2024 publication",
    "title": "Rotator cuff collagen augmentation",
    "summary": "At about one year, MRI showed retears in 5 of 60 patients receiving a collagen implant and 16 of 62 with repair alone. Reported clinical outcomes were similar.",
    "scope": "The trial addresses the specific implant and rotator cuff population studied. Other materials and indications require their own evidence.",
    "sources": [
      {
        "label": "Randomized rotator cuff trial",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38158165/"
      }
    ],
    "topics": [
      "Medicine",
      "Sports medicine",
      "Biomaterials"
    ],
    "study": {
      "design": "Randomized comparison of rotator cuff repair with a bioinductive collagen implant versus repair alone in 124 patients.",
      "endpoint": "Structural retear on MRI at one year, assessed separately from clinical outcomes.",
      "review": "Check the two MRI denominators against enrollment and follow-up. Compare functional outcomes and the retear endpoint separately."
    }
  },
  {
    "id": "ENTHESIS",
    "track": "Orthopedics",
    "status": "Literature comparison",
    "era": "Recovered review",
    "title": "Tendon-to-bone interface and graded scaffolds",
    "summary": "The research brief mapped alignment, material gradients, and mineralization as candidate ways to reconstruct an attachment. The research question is how the interface transmits load after repair.",
    "scope": "Track morphology, mechanics, function, and adverse effects as distinct outcomes.",
    "sources": [
      {
        "label": "Interface review",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42593127/"
      }
    ],
    "topics": [
      "Chemistry"
    ]
  },
  {
    "id": "BIOELECTRIC",
    "track": "Orthopedics",
    "status": "Preclinical literature",
    "era": "2021 publication",
    "title": "Piezoelectric scaffolds and tendon repair",
    "summary": "The review included a motion-powered scaffold tested in tendon cells and an acute rat Achilles injury model. The publication has a correction.",
    "scope": "The model supports questions about activation and controls. A separate evidence path is needed for the proposed injectable enthesis scaffold.",
    "sources": [
      {
        "label": "Preclinical study",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34423493/"
      },
      {
        "label": "Published correction",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35388928/"
      }
    ],
    "topics": [
      "Chemistry",
      "Biomedical engineering",
      "Biomaterials",
      "Tissue engineering and regenerative medicine"
    ],
    "study": {
      "design": "Laboratory experiments with tendon cells and an acute rat Achilles injury model using a motion-powered piezoelectric scaffold.",
      "endpoint": "Repair-associated signaling and tissue response under the experimental conditions.",
      "review": "Read the published correction with the original paper. Check which controls separate electrical effects from mechanical loading and material properties."
    }
  },
  {
    "id": "ADHESIVE",
    "track": "Orthopedics",
    "status": "Preclinical literature",
    "era": "Recovered review",
    "title": "Biodegradable tendon-to-bone adhesives",
    "summary": "The earlier review compared an adhesive approach with fixation and scaffold strategies. The identified polyurethane study used a rat Achilles repair model.",
    "scope": "Track interface retention, durability, and failure mode separately. Clinical translation remains a research question.",
    "sources": [
      {
        "label": "Preclinical adhesive study",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42705628/"
      }
    ],
    "topics": [
      "Chemistry"
    ]
  },
  {
    "id": "CARTILAGE",
    "track": "Orthopedics",
    "status": "Literature comparison",
    "era": "Recovered review",
    "title": "Cartilage restoration and MACI",
    "summary": "The orthopedic work included cartilage restoration as a separate repair pathway and MACI as an example of a cellularized scaffold with a specific knee indication.",
    "scope": "Cartilage repair outcomes have their own population, endpoints, and safety conditions.",
    "sources": [
      {
        "label": "FDA product record",
        "url": "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane"
      }
    ],
    "topics": [
      "Medicine"
    ]
  },
  {
    "id": "MENISCUS",
    "track": "Orthopedics",
    "status": "Literature comparison",
    "era": "Recovered review",
    "title": "Meniscal root fixation",
    "summary": "The research discussion identified meniscal root repair as another attachment problem. It raises separate questions about fixation, structural extrusion, and patient outcomes.",
    "scope": "Keep repair technique, anatomy, comparators, and follow-up explicit.",
    "sources": [
      {
        "label": "Systematic review of meniscal root repair",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42186019/"
      }
    ],
    "topics": [
      "Medicine"
    ]
  },
  {
    "id": "NERVE",
    "track": "Orthopedics",
    "status": "Adjacent research",
    "era": "Recovered review",
    "title": "Peripheral nerve regeneration and stimulation",
    "summary": "Nerve conduits and electrical stimulation appeared in the adjacent research map. A human carpal tunnel stimulation study is one separate example of measuring reinnervation and function.",
    "scope": "The nerve study concerns its own setting. Keep neurophysiologic and functional outcomes separate when comparing technologies.",
    "sources": [
      {
        "label": "Human stimulation trial",
        "url": "https://pubmed.ncbi.nlm.nih.gov/19800329/"
      }
    ],
    "topics": [
      "Medicine"
    ]
  },
  {
    "id": "DELIVERY",
    "track": "Orthopedics",
    "status": "Research hypothesis",
    "era": "Recovered review",
    "title": "Minimally invasive delivery and injectable material",
    "summary": "Rob’s earlier idea was to ask whether injectable or minimally invasive electroactive material could be positioned at an attachment and respond to local activation. The discussion also raised ultrasound-guided delivery and dynamic loading.",
    "scope": "Specify placement, retention, active and matched inactive controls, mechanical function, and stopping criteria before any proposed bench study.",
    "sources": [
      {
        "label": "Orthopedic study plan",
        "url": "https://chatgpt.com/space/page_8f6d056995248191b18656b1f27e44ac"
      }
    ]
  },
  {
    "id": "WMR-001",
    "track": "Orthopedics",
    "status": "Protocol draft",
    "era": "Founding release",
    "title": "From synthetic ligament reconstruction to bioelectrically assisted tissue regeneration",
    "summary": "The internal narrative review and founding protocol synthesize the historical and modern repair pathways. WMR-001 asks which measures establish durable attachment and whether a controlled scaffold comparison is warranted.",
    "scope": "Current work is literature review, source extraction, and study design.",
    "sources": [
      {
        "label": "Research workspace",
        "url": "https://chatgpt.com/space/page_8f6d056995248191b18656b1f27e44ac"
      }
    ]
  },
  {
    "id": "ENT-2026",
    "track": "Neuroscience",
    "status": "Archived hypothesis",
    "era": "June 2026",
    "title": "Neurodevelopment, hearing, and ENT differential research",
    "summary": "Earlier research discussions explored how developmental history, acquired conditions, hearing or ear problems, and related symptoms might be distinguished in a literature review. Feeding, reflux, and inflammatory or infectious pathways were logged as separate questions.",
    "scope": "Historical research notes and hypotheses. The record supplies no finding that formula, reflux, infection, or ENT conditions cause autism.",
    "sources": [
      {
        "label": "AAP clinical report for context",
        "url": "https://publications.aap.org/pediatrics/article-abstract/145/1/e20193447/36917"
      },
      {
        "label": "PubMed citation",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31843864/"
      }
    ],
    "topics": [
      "Brain biology and neurobiology",
      "Medicine"
    ]
  },
  {
    "id": "CONSC-A",
    "track": "Neuroscience",
    "status": "Literature comparison",
    "era": "2013 publication",
    "title": "Measuring brain state during sleep, anesthesia, and impaired responsiveness",
    "summary": "The cited study evaluates an EEG-based measure of brain responses across sleep, anesthesia, and disorders of consciousness.",
    "scope": "Compare study populations, measurement definitions, and limits on interpreting individual results.",
    "sources": [
      {
        "label": "Casali et al. · Published measurement study",
        "url": "https://pubmed.ncbi.nlm.nih.gov/23946194/"
      }
    ],
    "topics": [
      "Brain biology and neurobiology",
      "Medicine",
      "Pharma and pharmacology"
    ],
    "provenance": {"label": "Published research", "detail": "PubMed PMID 23946194"}
  },
  {
    "id": "CONSC-B",
    "track": "Neuroscience",
    "status": "Literature comparison",
    "era": "2015–2022 publications",
    "title": "Attention, report, and human neuroscience",
    "summary": "Compare a review of no-report methods with a human visual-perception study using fMRI and eye measurements.",
    "scope": "Distinguish reported experience, observed behavior, and measured neural activity. Review assumptions used to infer perception when no report was required.",
    "sources": [
      {
        "label": "Tsuchiya et al. · No-report paradigms review",
        "url": "https://pubmed.ncbi.nlm.nih.gov/26585549/"
      },
      {
        "label": "Human visual perception · Published fMRI study",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36446792/"
      }
    ],
    "topics": [
      "Brain biology and neurobiology"
    ],
    "provenance": {"label": "Published research", "detail": "PubMed PMIDs 26585549 and 36446792"}
  },
  {
    "id": "CMD",
    "track": "Neuroscience",
    "status": "Literature comparison",
    "era": "2024 publication",
    "title": "Covert responses in disorders of consciousness",
    "summary": "A published study of cognitive motor dissociation compares behavioral assessments with measures of command-following in people with disorders of consciousness.",
    "scope": "A research comparison for methods and interpretation. Clinical assessment belongs in an approved clinical setting.",
    "sources": [
      {
        "label": "Cognitive motor dissociation study",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39141852/"
      }
    ],
    "topics": [
      "Brain biology and neurobiology",
      "Medicine"
    ]
  },
  {
    "id": "COGITATE",
    "track": "Neuroscience",
    "status": "Literature comparison",
    "era": "2025 publication",
    "title": "Competing theories and preregistered predictions",
    "summary": "The archived reviews and evidence desk include adversarial testing as a way to make theories compete on shared observations.",
    "scope": "The Cogitate study addresses its prespecified human neuroscience predictions.",
    "sources": [
      {
        "label": "Cogitate Consortium study",
        "url": "https://doi.org/10.1038/s41586-025-08888-1"
      },
      {
        "label": "PubMed citation",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40307561/"
      }
    ],
    "topics": [
      "Brain biology and neurobiology"
    ]
  },
  {
    "id": "BRAIN-FRONTAL",
    "track": "Brain biology and neurobiology",
    "status": "Recovered research synthesis",
    "era": "April 2026",
    "title": "Frontal cortex and inhibitory control",
    "summary": "The earlier literature synthesis maps frontal organization, prefrontal and basal ganglia anatomy, thalamic circuits, attention, and cerebellar contributions to inhibitory control.",
    "scope": "Secondary literature synthesis. Record the measurement methods and study populations from the underlying research.",
    "sources": [],
    "provenance": {
      "label": "Medical excerpt",
      "detail": "April 2026 frontal-systems literature synthesis, excerpt 135."
    }
  },
  {
    "id": "PARKINSON-CIRCUITS",
    "track": "Parkinson’s",
    "status": "Recovered research synthesis",
    "era": "April 2026",
    "title": "Parkinson’s disease and cortico–basal ganglia circuits",
    "summary": "The frontal-systems work used Parkinson’s disease as a comparison for dopaminergic disruption of basal ganglia loops. It discussed the direct, indirect, and hyperdirect pathways alongside movement and executive control.",
    "scope": "Recovered literature discussion and circuit-level comparison. Disease-specific primary studies and further prior work remain to be attached.",
    "sources": [],
    "provenance": {
      "label": "Medical excerpt",
      "detail": "April 2026 frontal-systems literature synthesis, section on system pathologies."
    },
    "topics": [
      "Brain biology and neurobiology",
      "Medicine"
    ]
  },
  {
    "id": "MS-RECOVERY",
    "track": "Multiple sclerosis",
    "status": "Source recovery pending",
    "era": "Prior work identified by Rob",
    "title": "Multiple sclerosis research",
    "summary": "Rob identified multiple sclerosis as a distinct body of earlier research. This entry keeps its place in the medical archive while the original conversations, notes, and deliverables are located.",
    "scope": "Study questions, dates, methods, and findings will be recorded from the originals.",
    "sources": [],
    "provenance": {
      "label": "Owner-identified research lane",
      "detail": "Original MS research material was not located in the accessible search results or exported chat sample."
    }
  },
  {
    "id": "AUTISM-BIO-RECOVERY",
    "track": "Autism bioengineering",
    "status": "Source recovery pending",
    "era": "Prior work identified by Rob",
    "title": "Biological autism bioengineering record",
    "summary": "This record tracks the recovery of the original biological and bioengineering research notes.",
    "scope": "Record the biological methods, study population, measurements, and limits once the original material is recovered.",
    "sources": [],
    "provenance": {
      "label": "Owner-identified research lane",
      "detail": "The source pass did not recover a biological experiment, dataset, or a complete set of the earlier bioengineering notes."
    }
  },
  {
    "id": "CHEM-CLANE",
    "track": "Chemistry",
    "status": "Recovered hypothesis map",
    "era": "June 2026",
    "title": "Neurochemistry and metabolic injury questions",
    "summary": "The earlier C-lane grouped medication and toxin exposure, mitochondrial and fatty-acid oxidation questions, and liver–ammonia–brain pathways as distinct differential research topics.",
    "scope": "A historical hypothesis map. It supplies no diagnosis, causal conclusion, or validated screening pathway.",
    "sources": [],
    "provenance": {
      "label": "Conversation excerpt recovered",
      "detail": "June 5, 2026 C-lane and 1970–2026 diagnostic problem discussion."
    },
    "topics": [
      "Brain biology and neurobiology",
      "Medicine",
      "Pharma and pharmacology"
    ]
  },
  {
    "id": "CHEM-FOOD",
    "track": "Chemistry",
    "status": "Recovered literature and design notes",
    "era": "March 2026",
    "title": "Fermentation, grain chemistry, and nutrition",
    "summary": "The earlier food-chemistry work discussed gluten protein fractions, sourdough fermentation, phytic acid, tannins, seed oils, and lipid oxidation. It also sketched formulation comparisons with different grains and seed additions.",
    "scope": "Literature and formulation discussion. No new composition assay, glycemic study, or clinical validation was recorded in the recovered excerpt.",
    "sources": [],
    "provenance": {
      "label": "Conversation excerpt recovered",
      "detail": "March 24, 2026 research discussion on grain proteins, fermentation, and formulation."
    },
    "topics": [
      "Supplements and nutrition"
    ]
  },
  {
    "id": "QB-CRYPTO",
    "track": "Quantum biology",
    "status": "Recovered literature discussion",
    "era": "April 2026",
    "title": "Cryptochrome and avian magnetoreception",
    "summary": "The prior discussion compared a spin-sensitive radical-pair mechanism in cryptochrome with the broader question of how birds sense a magnetic field.",
    "scope": "The linked study concerns magnetic sensitivity in vitro. In vivo navigation and the full biological mechanism have separate evidence requirements.",
    "sources": [
      {
        "label": "Nature cryptochrome study",
        "url": "https://www.nature.com/articles/s41586-021-03618-9"
      }
    ],
    "provenance": {
      "label": "Conversation excerpt recovered",
      "detail": "April 16, 2026 discussion of avian magnetoreception and radical pairs."
    }
  },
  {
    "id": "QB-MECHANISMS",
    "track": "Quantum biology",
    "status": "Recovered literature comparison",
    "era": "April 2026",
    "title": "Photosynthetic coherence and enzyme tunneling",
    "summary": "The earlier quantum biology discussion compared photosynthetic excitonic coherence, enzyme tunneling, and avian magnetoreception as distinct mechanism candidates. Each uses its own observables and controls.",
    "scope": "The discussion supplies a map of questions. Transfer between biological systems requires separate evidence.",
    "sources": [],
    "provenance": {
      "label": "Conversation excerpt recovered",
      "detail": "April 16, 2026 quantum biology comparison."
    }
  },
  {
    "id": "QB-TUBULIN",
    "track": "Quantum biology",
    "status": "Preclinical and laboratory literature",
    "era": "April–July 2026",
    "title": "Microtubules in anesthesia and photophysics experiments",
    "summary": "The earlier review considered a rat anesthesia study and a tryptophan photophysics study. They measured different outcomes at different scales.",
    "scope": "Keep animal behavior and molecular measurements separate. Each result applies to the conditions and materials of its own study.",
    "sources": [
      {
        "label": "Rat anesthesia study",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39147581/"
      },
      {
        "label": "Tryptophan photophysics paper",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11075083/"
      }
    ],
    "provenance": {
      "label": "Conversation excerpts recovered",
      "detail": "April–July 2026 review of the linked studies."
    },
    "topics": [
      "Brain biology and neurobiology",
      "Pharma and pharmacology"
    ]
  },
  {
    "id": "MED-NUTRITION",
    "track": "Supplements and nutrition",
    "status": "Recovered research discussion",
    "era": "March 2026",
    "title": "Nutrition, supplements, and neuroplasticity",
    "summary": "The earlier learning-nutrition discussion examined BDNF as a research topic and considered omega-3s, B vitamins, flavonoids, polyphenols, and curcumin as evidence-review subjects.",
    "scope": "This archive entry documents the topics considered. Dose, interactions, population, endpoints, and clinical efficacy require specific sources. The NIH resource is background reading.",
    "sources": [
      {
        "label": "NIH dietary supplement fact sheets",
        "url": "https://ods.od.nih.gov/factsheets/list-all/"
      }
    ],
    "provenance": {
      "label": "Conversation excerpt recovered",
      "detail": "March 25, 2026 neuroplasticity and learning-nutrition discussion."
    },
    "topics": [
      "Brain biology and neurobiology",
      "Chemistry"
    ]
  },
  {
    "id": "MS-REBUILD",
    "track": "Multiple sclerosis",
    "status": "Published clinical trial",
    "era": "2017",
    "title": "ReBUILD · Clemastine and visual signal conduction",
    "summary": "Clemastine shortened the latency delay by 1.7 ms per eye (95% CI 0.5 to 2.9, p = 0.0048). The trial reported fatigue and no serious adverse events.",
    "scope": "This electrophysiologic endpoint measures conduction. The trial did not establish a disability benefit or safety in progressive MS.",
    "sources": [
      {
        "label": "Green et al. · The Lancet",
        "url": "https://pubmed.ncbi.nlm.nih.gov/29029896/"
      }
    ],
    "topics": [
      "Medicine",
      "Pharma and pharmacology",
      "Brain biology and neurobiology",
      "Neurology",
      "Neuroimmunology"
    ],
    "study": {
      "design": "Randomized, double-blind crossover trial in 50 people with multiple sclerosis and chronic demyelinating optic neuropathy. All 50 completed the study.",
      "endpoint": "P100 latency delay on visual evoked potentials, measured in milliseconds per eye.",
      "review": "Check the crossover analysis for treatment carryover. Compare the enrolled population and safety monitoring with TRAP-MS before comparing interpretations."
    }
  },
  {
    "id": "MS-TRAP-SAFETY",
    "track": "Multiple sclerosis",
    "status": "Published clinical safety study",
    "era": "2025",
    "title": "TRAP-MS · Clemastine stopping rules",
    "summary": "Three of nine participants on clemastine triggered safety stopping rules. Investigators halted the clemastine arm.",
    "scope": "A safety signal in a small selected progressive-MS cohort. The study does not estimate general-population risk.",
    "sources": [
      {
        "label": "Kocot et al. · Journal of Clinical Investigation",
        "url": "https://www.jci.org/articles/view/183941/version/1"
      }
    ],
    "topics": [
      "Medicine",
      "Pharma and pharmacology",
      "Brain biology and neurobiology",
      "Neurology",
      "Neuroimmunology"
    ],
    "study": {
      "design": "Clemastine treatment arm of a platform study in patients with MS whose disability was worsening independently of relapse activity.",
      "endpoint": "Within-patient change in the rate of disability progression, measured using the Composite Functional Scale (CombiWISE), with prespecified safety stopping rules.",
      "review": "Check the thresholds, follow-up window, and baseline progression for the three cases. Separate clinical observations from the paper’s mechanistic experiments."
    }
  },
  {
    "id": "MS-ORATORIO",
    "track": "Multiple sclerosis",
    "status": "Published clinical trial",
    "era": "2017",
    "title": "ORATORIO · Ocrelizumab and disability progression",
    "summary": "Confirmed progression occurred in 32.9% of the ocrelizumab group and 39.3% of the placebo group. Hazard ratio 0.76 (95% CI 0.59 to 0.98).",
    "scope": "The trial measured disability progression in the enrolled population. It did not directly measure remyelination.",
    "sources": [
      {
        "label": "Montalban et al. · New England Journal of Medicine",
        "url": "https://doi.org/10.1056/NEJMoa1606468"
      },
      {
        "label": "PubMed citation",
        "url": "https://pubmed.ncbi.nlm.nih.gov/28002688/"
      }
    ],
    "topics": [
      "Medicine",
      "Pharma and pharmacology",
      "Neurology",
      "Neuroimmunology"
    ],
    "study": {
      "design": "Phase 3 randomized placebo-controlled trial in 732 participants with primary progressive MS (488 assigned ocrelizumab, 244 placebo).",
      "endpoint": "Time to disability progression confirmed at 12 weeks, based on the Expanded Disability Status Scale.",
      "review": "Extract the scale’s progression thresholds and confirmation window. Record which eligibility criteria limit applicability to other progressive-MS cohorts."
    }
  },
  {
    "id": "PD-LIXIPARK",
    "track": "Parkinson’s",
    "status": "Published clinical trial",
    "era": "2024",
    "title": "LIXIPARK · Lixisenatide in early Parkinson’s",
    "summary": "Motor scores changed by −0.04 with lixisenatide and +3.04 with placebo. The difference favoring lixisenatide was 3.08 points (95% CI 0.86 to 5.30). Nausea affected 46% of participants receiving lixisenatide.",
    "scope": "The trial detected a difference on the motor score under these conditions. It did not establish disease modification.",
    "sources": [
      {
        "label": "Meissner et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38598572/"
      }
    ],
    "topics": [
      "Medicine",
      "Pharma and pharmacology",
      "Brain biology and neurobiology",
      "Neurology"
    ],
    "study": {
      "design": "Phase 2 randomized, double-blind trial in 156 people with early Parkinson’s who were taking stable symptomatic medication (78 per group).",
      "endpoint": "Twelve-month change in MDS-UPDRS Part III motor score while on usual Parkinson’s medication. Higher scores reflect greater motor impairment.",
      "review": "Check the possible effects of side-effect-related unblinding and the prespecified washout assessment before interpreting the motor-score difference."
    }
  },
  {
    "id": "PD-EXENATIDE-P3",
    "track": "Parkinson’s",
    "status": "Expression of Concern",
    "era": "2025",
    "title": "Exenatide-PD3 · A 96-week phase 3 test",
    "summary": "The 2025 paper reported an adjusted difference of +0.92 points (95% CI −1.56 to +3.39). The Lancet issued an Expression of Concern in June 2026.",
    "scope": "Read the editorial notice alongside the original report. The archive preserves the reported endpoint for methods comparison.",
    "sources": [
      {
        "label": "Vijiaratnam et al. · The Lancet",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39919773/"
      },
      {
        "label": "The Lancet editors · Expression of Concern",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42330995/"
      }
    ],
    "topics": [
      "Medicine",
      "Pharma and pharmacology",
      "Brain biology and neurobiology",
      "Neurology"
    ],
    "study": {
      "design": "Phase 3 randomized, double-blind trial in 194 people with Parkinson’s (97 per group), comparing weekly exenatide with placebo.",
      "endpoint": "Change in MDS-UPDRS Part III motor score at 96 weeks, assessed off dopaminergic medication.",
      "review": "Check the editorial notice, assessment medication state, follow-up, and missing motor assessments before interpreting the report."
    }
  },
  {
    "id": "WMRI-PD-001",
    "track": "Parkinson’s",
    "status": "Ready for independent review",
    "era": "2026",
    "title": "Comparing motor outcomes in two Parkinson’s trials · Version 1",
    "summary": "A Waddell evidence pilot compares the primary motor assessments in LIXIPARK and Exenatide-PD3. It documents medication state, analysis counts, follow-up, and the editorial notice for Exenatide-PD3.",
    "scope": "Methods comparison of two selected trial records using public aggregate results. Independent review is pending.",
    "projectVersion": "/projects/parkinsons-trial-endpoints/v1",
    "sources": [
      {
        "label": "LIXIPARK original report",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38598572/"
      },
      {
        "label": "Exenatide-PD3 original report",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39919773/"
      },
      {
        "label": "The Lancet editors · Expression of Concern",
        "url": "https://pubmed.ncbi.nlm.nih.gov/42330995/"
      }
    ],
    "topics": ["Neurology", "Pharma and pharmacology"],
    "study": {
      "design": "Compare the published primary motor assessments of two selected randomized trials.",
      "endpoint": "Record timing, medication state, available outcomes, and each published between-group estimate on a common directional scale.",
      "review": "Verify the extraction, the effect-direction conversion, and the current editorial status of both source reports."
    }
  },
  {
    "id": "AUT-FOXG1-ORGANOID",
    "track": "Autism bioengineering",
    "status": "Published laboratory study",
    "era": "2015",
    "title": "FOXG1 and neuronal differentiation in organoids",
    "summary": "The study reported higher FOXG1 expression and greater GABAergic neuron production in the autism-derived organoids. Reducing FOXG1 expression changed the differentiation outcome in culture.",
    "scope": "A small selected cohort and an experimental cell model. The findings address the cultures and perturbation studied.",
    "sources": [
      {
        "label": "Mariani et al. · Cell",
        "url": "https://europepmc.org/articles/PMC4519016"
      }
    ],
    "topics": [
      "Brain biology and neurobiology",
      "Developmental biology",
      "Stem cells and organoids",
      "Cell and molecular biology"
    ],
    "study": {
      "design": "Researchers grew brain organoids from induced pluripotent stem cells from four families. They used two to three cell lines per person. Each family included a proband with idiopathic autism and increased head circumference plus unaffected relatives.",
      "endpoint": "Gene expression and the relative production of neuronal lineages in culture, including a FOXG1 knockdown experiment.",
      "review": "Separate family, donor, cell-line, and organoid counts. Check which controls support attributing the differentiation result to FOXG1 knockdown."
    }
  },
  {
    "id": "AUT-ORGANOID-13F",
    "track": "Autism bioengineering",
    "status": "Published laboratory study",
    "era": "2023",
    "title": "Forebrain organoids across 13 autism families",
    "summary": "Differences in excitatory lineage balance between boys and their fathers went in opposite directions in the macrocephalic and normocephalic groups.",
    "scope": "A developmental finding in a cultured model. Its interpretation depends on the cohort, differentiation conditions, and unit of analysis.",
    "sources": [
      {
        "label": "Jourdon et al. · Nature Neuroscience",
        "url": "https://www.nature.com/articles/s41593-023-01399-0"
      },
      {
        "label": "NIMH Data Archive study record",
        "url": "https://nda.nih.gov/study.html?id=1482"
      },
      {
        "label": "PubMed citation",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37563294/"
      }
    ],
    "topics": [
      "Brain biology and neurobiology",
      "Developmental biology",
      "Stem cells and organoids",
      "Cell and molecular biology"
    ],
    "study": {
      "design": "Stem-cell-derived forebrain organoids from autistic boys and their unaffected fathers in 13 families. Researchers analyzed differences by head size.",
      "endpoint": "Single-cell RNA sequencing was used to examine cell composition and excitatory neuron lineage balance during early differentiation.",
      "review": "Check donor-level statistics and batch effects. Confirm any participant overlap with the earlier FOXG1 study before calling the findings independent."
    }
  },
  {
    "id": "SUP-COSMOS-WEB",
    "track": "Supplements and nutrition",
    "status": "Published clinical trial",
    "era": "2023",
    "title": "COSMOS-Web · Multivitamins and word recall",
    "summary": "The tested multivitamin group performed better on the primary one-year immediate recall outcome (p = 0.025). Other secondary cognitive outcomes showed no significant effects.",
    "scope": "The result concerns the tested formulation and recall measure. The study did not establish an effect on dementia incidence or functional independence.",
    "sources": [
      {
        "label": "Yeung et al. · American Journal of Clinical Nutrition",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37244291/"
      }
    ],
    "topics": [
      "Medicine",
      "Brain biology and neurobiology",
      "Geriatrics and aging",
      "Clinical nutrition and dietetics",
      "Dementia and cognitive disorders"
    ],
    "study": {
      "design": "Randomized placebo-controlled study of daily multivitamin supplementation in 3,562 older adults who took web-based cognitive tests.",
      "endpoint": "Change in immediate word recall at one year on the Modified Rey test.",
      "review": "Extract the adjusted difference in words recalled and the confidence interval. Check the secondary outcomes and attrition before judging practical significance."
    }
  },
  {
    "id": "SUP-VITAL-OMEGA3",
    "track": "Supplements and nutrition",
    "status": "Published clinical trial",
    "era": "2022",
    "title": "VITAL · Marine omega-3 and cognitive change",
    "summary": "The pooled between-group difference in annual global cognitive change was −0.01 standard units (95% CI −0.02 to +0.003, p = 0.15).",
    "scope": "The trial did not detect a global cognitive benefit for the marine omega-3 formulation and follow-up studied.",
    "sources": [
      {
        "label": "Kang et al. · American Journal of Clinical Nutrition",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35415212/"
      }
    ],
    "topics": [
      "Medicine",
      "Brain biology and neurobiology",
      "Geriatrics and aging",
      "Clinical nutrition and dietetics",
      "Dementia and cognitive disorders"
    ],
    "study": {
      "design": "Two cognitive substudies of a randomized placebo-controlled trial. Assessments were conducted by telephone in 3,424 participants and in person in 794.",
      "endpoint": "Annual change in a standardized composite of cognitive tests, with mean follow-up of 2.8 and 2.0 years in the respective substudies.",
      "review": "Check how the global score pooled different tests. When comparing with COSMOS-Web, account for different formulations, endpoints, and follow-up."
    }
  },
  {
    "id": "QB-CELL-MAGFIELD",
    "track": "Quantum biology",
    "status": "Published laboratory study",
    "era": "2021",
    "title": "Magnetic fields and fluorescence in living cells",
    "summary": "The fitted curve gave a half-saturation field of 18 mT and a 3.7% saturation response. The authors interpreted the results as consistent with a radical-pair mechanism.",
    "scope": "An in vitro optical result. The fitted quantities are estimates and the mechanism is an interpretation of the measurements.",
    "sources": [
      {
        "label": "Ikeya and Woodward · PNAS",
        "url": "https://pubmed.ncbi.nlm.nih.gov/33397812/"
      }
    ],
    "topics": [
      "Chemistry",
      "Biochemistry",
      "Cell and molecular biology",
      "Analytical chemistry"
    ],
    "study": {
      "design": "Single-cell fluorescence experiments with HeLa cells and applied magnetic fields up to 25 mT.",
      "endpoint": "Change in cellular autofluorescence under the field. A fitted response curve estimated half-saturation and the saturation response.",
      "review": "Check illumination and field-switching controls, variation between cells, and the uncertainty in the fitted parameters. Identify a control that would discriminate between the proposed mechanism and a competing explanation."
    }
  },
  {
    "id": "CHEM-MAOB-STRUCTURE",
    "track": "Chemistry",
    "status": "Published laboratory study",
    "era": "2007",
    "title": "MAO-B structures with safinamide and coumarins",
    "summary": "The three compounds had MAO-B Kᵢ values of 0.1 to 0.5 μM, 30 to 700 times lower than their MAO-A values. The safinamide structure was solved at 1.60 Å.",
    "scope": "Biochemical selectivity and a structural observation under laboratory conditions. Patient outcomes require clinical evidence.",
    "sources": [
      {
        "label": "Binda et al. · Journal of Medicinal Chemistry",
        "url": "https://pubmed.ncbi.nlm.nih.gov/17915852/"
      },
      {
        "label": "Protein Data Bank 2V5Z",
        "url": "https://www.rcsb.org/structure/2V5Z"
      }
    ],
    "topics": [
      "Pharma and pharmacology",
      "Brain biology and neurobiology",
      "Medicinal chemistry",
      "Biochemistry",
      "Drug discovery and development"
    ],
    "study": {
      "design": "X-ray crystallography of human MAO-B bound to safinamide or either of two coumarin analogues, combined with enzyme inhibition assays.",
      "endpoint": "Competitive inhibition constants (Kᵢ) for MAO-B and MAO-A, plus the binding pose in the MAO-B structures.",
      "review": "Match each Kᵢ and selectivity value to its compound. Inspect the deposited structure and confirm whether the assay conditions allow comparison with the rasagiline study."
    }
  },
  {
    "id": "CHEM-MAOB-STEREO",
    "track": "Chemistry",
    "status": "Published laboratory study",
    "era": "2004",
    "title": "Rasagiline stereochemistry and MAO inactivation",
    "summary": "The authors reported that MAO-B favored the R-enantiomer over the S-enantiomer by 2,500-fold, compared with 17-fold for MAO-A in the inactivation assays.",
    "scope": "These are comparisons between enantiomers within each enzyme under the reported assay conditions. The study examined purified enzymes.",
    "sources": [
      {
        "label": "Hubálek et al. · Journal of Medicinal Chemistry",
        "url": "https://pubmed.ncbi.nlm.nih.gov/15027867/"
      }
    ],
    "topics": [
      "Pharma and pharmacology",
      "Brain biology and neurobiology",
      "Medicinal chemistry",
      "Biochemistry",
      "Drug discovery and development"
    ],
    "study": {
      "design": "In vitro assays of purified recombinant human MAO-A and MAO-B with rasagiline and four analogues, including its S-enantiomer.",
      "endpoint": "Enzyme inactivation kinetics and spectroscopy of inhibitor–enzyme complexes.",
      "review": "Identify the kinetic quantity used to calculate the fold differences. Distinguish time-dependent inactivation from the competitive Kᵢ reported for safinamide."
    }
  },
  {
    "id": "CARD-SPRINT",
    "track": "Cardiology",
    "status": "Published clinical trial",
    "era": "2015",
    "title": "SPRINT · Blood pressure targets and cardiovascular events",
    "summary": "The primary event rates were 1.65% and 2.19% per year in the intensive and standard groups. Hazard ratio 0.75 (95% CI 0.64 to 0.89).",
    "scope": "The trial population and blood pressure measurement protocol define the setting. Several serious adverse events, including acute kidney injury, were more frequent with intensive treatment.",
    "sources": [
      {
        "label": "SPRINT Research Group · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/26551272/"
      }
    ],
    "topics": [
      "Medicine",
      "Preventive medicine",
      "Vascular medicine",
      "General internal medicine"
    ],
    "study": {
      "design": "Randomized comparison in 9,361 adults at elevated cardiovascular risk without diabetes. The systolic blood pressure targets were below 120 or below 140 mm Hg.",
      "endpoint": "Time to the first event in a composite of major cardiovascular events or cardiovascular death.",
      "review": "Check the event adjudication, measurement protocol, and adverse-event counts. Reconcile the composite result with its components."
    }
  },
  {
    "id": "KIDNEY-DAPA-CKD",
    "track": "Nephrology",
    "status": "Published clinical trial",
    "era": "2020",
    "title": "DAPA-CKD · Kidney and cardiovascular outcomes",
    "summary": "The composite endpoint occurred in 9.2% on dapagliflozin and 14.5% on placebo. Hazard ratio 0.61 (95% CI 0.51 to 0.72) over a median 2.4 years.",
    "scope": "The composite and eligibility criteria define the population and outcomes to which the result applies.",
    "sources": [
      {
        "label": "Heerspink et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/32970396/"
      }
    ],
    "topics": [
      "Medicine",
      "Endocrinology and metabolism",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "Randomized placebo-controlled trial in 4,304 adults with chronic kidney disease and elevated urinary albumin, with or without type 2 diabetes.",
      "endpoint": "A sustained estimated glomerular filtration rate decline of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.",
      "review": "Separate the endpoint components and check eligibility, subgroup precision, and the criteria for early stopping."
    }
  },
  {
    "id": "ONC-KEYNOTE-024",
    "track": "Medical oncology",
    "status": "Published clinical trial",
    "era": "2016",
    "title": "KEYNOTE-024 · First-line treatment for selected lung cancer",
    "summary": "Median progression-free survival was 10.3 months with pembrolizumab and 6.0 months with chemotherapy. Hazard ratio 0.50 (95% CI 0.37 to 0.68).",
    "scope": "Evidence for the selected biomarker-defined population and trial comparator.",
    "sources": [
      {
        "label": "Reck et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/27718847/"
      }
    ],
    "topics": [
      "Medicine",
      "Pulmonary and respiratory medicine",
      "Biomarkers and diagnostics",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "Randomized, open-label phase 3 study in 305 people with advanced non-small-cell lung cancer, PD-L1 expression in at least 50% of tumor cells, and specified exclusion criteria for EGFR and ALK.",
      "endpoint": "Progression-free survival assessed by blinded, independent central review.",
      "review": "Check central review criteria, crossover after progression, and which conclusions require overall-survival follow-up."
    }
  },
  {
    "id": "ID-RECOVERY-DEX",
    "track": "Infectious diseases",
    "status": "Published clinical trial",
    "era": "2021",
    "title": "RECOVERY · Dexamethasone and 28-day mortality",
    "summary": "Mortality was 22.9% with dexamethasone and 25.7% with usual care. Age-adjusted rate ratio 0.83 (95% CI 0.75 to 0.93). Results differed by respiratory support at baseline.",
    "scope": "The study concerned hospitalized patients. Respiratory-support strata and the trial period matter for interpretation.",
    "sources": [
      {
        "label": "RECOVERY Collaborative Group · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/32678530/"
      }
    ],
    "topics": [
      "Medicine",
      "Hospital medicine",
      "Critical care",
      "Pulmonary and respiratory medicine",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "Open-label randomized trial in hospitalized patients with COVID-19, 2,104 assigned dexamethasone and 4,321 usual care.",
      "endpoint": "Death from any cause within 28 days after randomization.",
      "review": "Check subgroup denominators, respiratory support categories, and which contrasts were specified before the results were examined."
    }
  },
  {
    "id": "PREV-DPP",
    "track": "Preventive medicine",
    "status": "Published clinical trial",
    "era": "2002",
    "title": "Diabetes Prevention Program · Lifestyle and metformin",
    "summary": "Incidence was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively.",
    "scope": "The findings apply to the studied high-risk population and the structured intervention that was delivered.",
    "sources": [
      {
        "label": "Diabetes Prevention Program Research Group · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/11832527/"
      }
    ],
    "topics": [
      "Medicine",
      "Endocrinology and metabolism",
      "Diabetes",
      "Family medicine",
      "Clinical nutrition and dietetics",
      "Public health"
    ],
    "study": {
      "design": "Randomized comparison of placebo, metformin, and a structured lifestyle program in 3,234 adults with elevated fasting and post-load blood glucose.",
      "endpoint": "New type 2 diabetes over a mean follow-up of 2.8 years.",
      "review": "Check the diagnostic confirmation rules, intervention intensity, and whether relative effects match the reported absolute incidence rates."
    }
  },
  {
    "id": "PSY-STARD-LEVEL1",
    "track": "Psychiatry",
    "status": "Published clinical cohort",
    "era": "2006",
    "title": "STAR*D · Measuring remission on two scales",
    "summary": "The report gives remission rates of 28% on the Hamilton scale and 33% on the self-report scale.",
    "scope": "This step had no placebo comparison. The two remission estimates depend on the scale, threshold, and handling of incomplete assessments.",
    "sources": [
      {
        "label": "Trivedi et al. · American Journal of Psychiatry",
        "url": "https://pubmed.ncbi.nlm.nih.gov/16390886/"
      }
    ],
    "topics": [
      "Medicine",
      "Psychology and behavioral health",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "The first treatment step used measurement-based citalopram care in 2,876 analyzed adult outpatients with major depression.",
      "endpoint": "Remission at exit by a clinician-rated Hamilton scale and by the self-reported QIDS-SR, using each scale’s threshold.",
      "review": "Check participant inclusion, prespecified endpoints, scale-specific denominators, and missing exit ratings before comparing remission figures."
    }
  },
  {
    "id": "MAT-RSV-MATISSE",
    "track": "Obstetrics and maternal–fetal medicine",
    "status": "Published clinical trial",
    "era": "2023",
    "title": "MATISSE · Maternal RSV vaccination and infant outcomes",
    "summary": "Estimated efficacy for the severe endpoint was 81.8% through 90 days and 69.4% through 180 days. The broader medically attended illness endpoint did not meet its prespecified success criterion at 90 days.",
    "scope": "The result concerns the severe infant endpoint and tested vaccine. Each endpoint has its own success threshold and uncertainty interval.",
    "sources": [
      {
        "label": "Kampmann et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37018474/"
      }
    ],
    "topics": [
      "Medicine",
      "Pediatrics",
      "Neonatology",
      "Vaccinology",
      "Infectious diseases"
    ],
    "study": {
      "design": "Phase 3 double-blind, randomized maternal RSV prefusion F vaccine trial with outcomes assessed in infants.",
      "endpoint": "The severe medically attended RSV lower respiratory tract illness endpoint was assessed through 90 and 180 days after birth.",
      "review": "Compare the two primary endpoint definitions, confidence levels, and stopping rules. Review efficacy and safety evidence separately."
    }
  },
  {
    "id": "ALLERGY-PALISADE",
    "track": "Allergy and clinical immunology",
    "status": "Published clinical trial",
    "era": "2018",
    "title": "PALISADE · Peanut oral immunotherapy challenge",
    "summary": "The challenge endpoint was met by 67.2% of the active treatment group and 4.0% of the placebo group. Adverse events were frequent.",
    "scope": "A supervised challenge measured desensitization while receiving the studied treatment. It does not establish sustained tolerance after withdrawal.",
    "sources": [
      {
        "label": "PALISADE Group · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/30449234/"
      }
    ],
    "topics": [
      "Medicine",
      "Pediatrics",
      "Immunology"
    ],
    "study": {
      "design": "Randomized, double-blind, placebo-controlled oral immunotherapy trial. The primary efficacy analysis concerned participants aged 4 to 17 years.",
      "endpoint": "Proportion able to ingest at least 600 mg of peanut protein at an exit challenge without dose-limiting symptoms.",
      "review": "Compare the challenge threshold, withdrawn participants, and systemic adverse events. Distinguish challenge results from everyday outcomes."
    }
  },
  {
    "id": "PED-RSV-HARMONIE",
    "track": "Pediatrics",
    "status": "Published clinical trial",
    "era": "2023",
    "title": "HARMONIE · Infant RSV hospitalizations",
    "summary": "RSV-related hospitalization occurred in 11 of 4,037 infants assigned nirsevimab and 60 of 4,021 assigned standard care. Estimated efficacy was 83.2% (95% CI 67.8 to 92.0).",
    "scope": "The estimate concerns the prevention strategy, populations, seasonal setting, and clinical endpoint tested.",
    "sources": [
      {
        "label": "Drysdale et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38157500/"
      }
    ],
    "topics": [
      "General pediatrics",
      "Pediatric infectious diseases",
      "Pediatric pulmonology",
      "Infectious diseases",
      "Preventive medicine",
      "Vaccinology"
    ],
    "study": {
      "design": "Pragmatic randomized trial involving 8,058 infants in France, Germany, and the United Kingdom entering their first RSV season.",
      "endpoint": "Hospital admission for RSV-associated lower respiratory tract infection.",
      "review": "Check the trial’s hospitalization and laboratory criteria, the absolute event rates, and results by country."
    }
  },
  {
    "id": "DERM-SOLO",
    "track": "Dermatology",
    "status": "Published clinical trial",
    "era": "2016",
    "title": "SOLO 1 and SOLO 2 · Atopic dermatitis severity",
    "summary": "In SOLO 1, 38% assigned dupilumab every other week met the primary outcome, compared with 10% assigned placebo. The primary outcome also favored the tested regimens in SOLO 2.",
    "scope": "Clinical results in the enrolled adults under the study’s short-term conditions.",
    "sources": [
      {
        "label": "Simpson et al. · New England Journal of Medicine",
        "url": "https://doi.org/10.1056/NEJMoa1610020"
      },
      {
        "label": "PubMed citation",
        "url": "https://pubmed.ncbi.nlm.nih.gov/27690741/"
      }
    ],
    "topics": [
      "General dermatology",
      "Immunodermatology",
      "Allergy and clinical immunology",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "Two phase 3 randomized placebo-controlled trials in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatment. SOLO 1 enrolled 671 and SOLO 2 enrolled 708.",
      "endpoint": "Investigator’s Global Assessment score of clear or almost clear at week 16 plus an improvement of at least two points.",
      "review": "Compare the clinician-rated and patient-reported measures. Check missing outcomes and adverse-event reporting separately."
    }
  },
  {
    "id": "PLASTIC-MROC-TIMING",
    "track": "Plastic and reconstructive surgery",
    "status": "Published clinical cohort",
    "era": "2018",
    "title": "MROC · Timing of breast reconstruction",
    "summary": "Delayed reconstruction was associated with fewer overall and major complications after adjustment. Patient-reported outcomes were similar at two years.",
    "scope": "An observational comparison with different group sizes and clinical characteristics. Timing was not randomized.",
    "sources": [
      {
        "label": "Yoon et al. · The Breast",
        "url": "https://pubmed.ncbi.nlm.nih.gov/29102781/"
      }
    ],
    "topics": [
      "Reconstructive breast surgery",
      "Breast cancer",
      "Surgical oncology",
      "Cancer survivorship"
    ],
    "study": {
      "design": "Prospective multicenter comparison of 1,806 immediate and 151 delayed breast reconstructions.",
      "endpoint": "Surgical complications and patient-reported outcomes assessed through two years.",
      "review": "Check the adjustment variables, outcome timing, and whether procedure type or selection into delayed surgery could explain part of the result."
    }
  },
  {
    "id": "PLASTIC-TOPS",
    "track": "Craniofacial surgery",
    "status": "Published clinical trial",
    "era": "2023",
    "title": "TOPS · Timing of isolated cleft palate repair",
    "summary": "Among children with assessment data, insufficiency was observed in 21 of 235 (8.9%) assigned earlier repair and 34 of 226 (15.0%) assigned later repair.",
    "scope": "The trial concerned nonsyndromic isolated cleft palate in participating surgical settings.",
    "sources": [
      {
        "label": "Gamble et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37646677/"
      }
    ],
    "topics": [
      "Plastic and reconstructive surgery",
      "Pediatric surgery",
      "Pediatrics",
      "Speech and swallowing"
    ],
    "study": {
      "design": "Randomized timing comparison across 23 centers in Europe and South America in 558 infants with isolated cleft palate. Outcome assessors were blinded to the assigned group.",
      "endpoint": "Velopharyngeal insufficiency at five years on a standardized speech assessment.",
      "review": "Check the missing assessment counts, surgical standardization, and sensitivity of the result to the outcome definition."
    }
  },
  {
    "id": "PSY-ELEKTD",
    "track": "Psychiatry",
    "status": "Published clinical trial",
    "era": "2023",
    "title": "ELEKT-D · Comparing two treatments for resistant depression",
    "summary": "Response was reported in 55.4% in the ketamine group and 41.2% in the electroconvulsive therapy group. The trial met its prespecified noninferiority test.",
    "scope": "The trial’s design addresses noninferiority for the enrolled population and endpoint. It excludes psychotic depression.",
    "sources": [
      {
        "label": "Anand et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37224232/"
      }
    ],
    "topics": [
      "Depression and mood disorders",
      "Psychopharmacology",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "Open-label, randomized noninferiority trial in 403 patients referred for electroconvulsive therapy with nonpsychotic treatment-resistant major depression.",
      "endpoint": "Treatment response defined as a reduction of at least 50% on the self-reported QIDS-SR scale during the initial treatment phase.",
      "review": "Read the margin rationale, analysis population, cognitive outcomes, and durability data separately."
    }
  },
  {
    "id": "HERB-HYPERICUM-MDD",
    "track": "Herbology and medicinal plants",
    "status": "Published clinical trial",
    "era": "2002",
    "title": "Hypericum trial · Depressive symptoms",
    "summary": "Neither the tested Hypericum preparation nor the active comparator significantly differed from placebo on the primary measures.",
    "scope": "The study is specific to the preparation, dose, population, and duration. The active comparator’s result limits the trial’s ability to distinguish effective treatment from placebo.",
    "sources": [
      {
        "label": "Hypericum Depression Trial Study Group · JAMA",
        "url": "https://pubmed.ncbi.nlm.nih.gov/11939866/"
      }
    ],
    "topics": [
      "Integrative medicine",
      "Depression and mood disorders",
      "Psychiatry",
      "Pharmacognosy"
    ],
    "study": {
      "design": "Randomized double-blind study comparing a specified St John’s wort extract, sertraline, and placebo in 340 adult outpatients with major depressive disorder.",
      "endpoint": "Change in Hamilton Depression Rating Scale scores and the prespecified full-response measure.",
      "review": "Check extract standardization, outcomes, active-comparator results, and prior evidence before drawing cross-product conclusions."
    }
  },
  {
    "id": "HERB-INDINAVIR-PK",
    "track": "Herbal medicines and drug interactions",
    "status": "Published clinical trial",
    "era": "2000",
    "title": "St John’s wort and indinavir exposure",
    "summary": "The investigators reported a mean 57% reduction in indinavir exposure, measured by the area under the curve, during coadministration.",
    "scope": "Drug concentration measurements under the study conditions. The finding concerns the named products and does not measure treatment outcomes.",
    "sources": [
      {
        "label": "Piscitelli et al. · The Lancet",
        "url": "https://pubmed.ncbi.nlm.nih.gov/10683007/"
      }
    ],
    "topics": [
      "Herbology and medicinal plants",
      "Pharmacokinetics and pharmacodynamics",
      "Drug safety and pharmacovigilance",
      "Infectious diseases"
    ],
    "study": {
      "design": "A pharmacokinetic interaction study in healthy volunteers using indinavir and a St John’s wort preparation.",
      "endpoint": "Indinavir concentration-time area under the curve and extrapolated trough concentration.",
      "review": "Check the timing, preparation, concentration measurements, and how closely this experiment informs other products."
    }
  },
  {
    "id": "ONC-KEYNOTE-522",
    "track": "Breast cancer",
    "status": "Published clinical trial",
    "era": "2022",
    "title": "KEYNOTE-522 · Event-free survival in early triple-negative breast cancer",
    "summary": "Estimated event-free survival at 36 months was 84.5% with the studied pembrolizumab-based regimen and 76.8% with the placebo-based regimen. Hazard ratio 0.63 (95% CI 0.48 to 0.82).",
    "scope": "The comparison evaluates the full perioperative regimens in the trial population.",
    "sources": [
      {
        "label": "Schmid et al. · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35139274/"
      }
    ],
    "topics": [
      "Medical oncology",
      "Surgical oncology",
      "Cancer survivorship",
      "Pharma and pharmacology"
    ],
    "study": {
      "design": "Randomized phase 3 trial in 1,174 people with previously untreated stage II or III triple-negative breast cancer.",
      "endpoint": "Event-free survival, including progression, recurrence, a second primary cancer, or death as defined by the protocol.",
      "review": "Check the timing of events, stage distribution, adverse events, and how later overall survival follow-up changes interpretation."
    }
  },
  {
    "id": "RARE-STR1VE",
    "track": "Clinical genetics and rare diseases",
    "status": "Published clinical trial",
    "era": "2021",
    "title": "STR1VE · Motor milestones in infantile spinal muscular atrophy",
    "summary": "Thirteen of 22 infants reached the independent-sitting milestone reported in the study.",
    "scope": "Small, single-arm study with a historical comparator. Cohort and assessment differences matter.",
    "sources": [
      {
        "label": "Day et al. · The Lancet Neurology",
        "url": "https://pubmed.ncbi.nlm.nih.gov/33743238/"
      }
    ],
    "topics": [
      "Pediatric genetics",
      "Pediatrics",
      "Neuromuscular disorders",
      "Gene and cell therapies"
    ],
    "study": {
      "design": "Open-label single-arm multicenter phase 3 study in 22 infants with symptomatic spinal muscular atrophy and two copies of SMN2.",
      "endpoint": "Independent sitting for at least 30 seconds at the 18-month visit, with survival assessed separately.",
      "review": "Check how the historical cohort was selected, outcome definitions, missing assessments, and treatment-emergent events."
    }
  }
]